Entry | H01238 Disease |
---|---|
Related pathway | hsa04724 Glutamatergic synapse |
Gene | SHANK3 [HSA:85358] [KO:K15009] |
Other DBs | ICD-11: LD44.NY ICD-10: Q93.5 MeSH: C536801 OMIM: 606232 |
Reference | PMID:11431708 |
ICD-9: 758.39. ONSET AND PROGRESSION. Individuals with Phelan-McDermid syndrome generally have life-long complications associated with this disorder with no apparent life-threatening organic malformations. Individuals surviving to adulthood may not be able to function independently and may require supportive services.
General Discussion. Phelan-McDermid syndrome (PMS) is a rare genetic condition caused by a deletion or other structural change of the terminal end of chromosome 22 in the 22q13 region or a disease-causing mutation of the SHANK3 gene.
Phelan-McDermid Syndrome is a rare genetic disorder that involves a deletion of 22q13 or a mutation of the SHANK3 gene. DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM/ICD-10-CM CODING Molecular genetic testing (usually chromosome microarray analysis, or CMA); or Fluorescent in situ hybridization (FISH) test analysis.
The 22q13.3 deletion syndrome, also known as Phelan-McDermid syndrome, is a contiguous gene disorder resulting from deletion of the distal long arm of chromosome 22.
Phelan-McDermid syndrome (PMS) is a rare genetic condition that causes developmental and speech delays, behavioral problems and a weakened or no ability to feel pain or sweat. Phelan-McDermid syndrome is a congenital condition (condition that is present at birth) that can affect people of all genders.
Phelan-McDermid syndrome, also called 22q13 deletion syndrome, is a genetic disorder caused by deletion of part of chromosome 22 or a defect in a gene called SHANK3. The disorder can cause a wide range of symptoms varying in severity.
Because the genetic changes vary, Phelan-McDermid syndrome (PMS) symptoms vary too, and can cause a wide range of medical, intellectual, and behavioral challenges. People who have PMS often show symptoms in very early childhood, sometimes at birth and within the first six months of life.
According to the Phelan-McDermid Syndrome Registry, of 232 individuals with microarray results, 181 (79%) have terminal or interstitial deletions, 41 (18%) have unbalanced translocations or other structural abnormalities leading to deletion, and 7 (3%) have SHANK3 pathogenic variants. 7.
About 84 percent of people with Phelan-McDermid syndrome have autism2. The syndrome can also include developmental delay and unusual physical features.
In 2002, a group of parents suggested that the official name of the syndrome should be called Phelan-McDermid Syndrome, after Dr. Katy Phelan and researcher Heather McDermid from the University of Alberta. In 2003, 22q13 deletion syndrome officially became known as Phelan-McDermid Syndrome.
There have since been over 500 identified cases worldwide. The deletion occurs in equal frequency in males and females. It is now often referred to as Phelan-McDermid syndrome, named after the people who first described and characterised the disorder: Drs Katy Phelan and Heather McDermid.
Tests Used For DiagnosisThese tests are most commonly used to diagnose Phelan-McDermid syndrome (PMS):Chromosomal Microarray Analysis (CMA) is a genetic test that is most commonly used to diagnose PMS and involves only providing a small amount of blood.More items...
Generally, Phelan-McDermid syndrome will not be diagnosed prenatally. Testing usually is initiated as a result of trying to identify the cause of hypotonia or global developmental delay. Genetic testing may be performed by a variety of methods. The most common testing method is chromosomal microarray analysis (CMA).
Definition. Sotos syndrome (cerebral gigantism) is a rare genetic disorder caused by mutation in the NSD1 gene on chromosome 5. It is characterized by excessive physical growth during the first few years of life.Sotos Syndrome | National Institute of Neurological Disorders and Strokehttps://www.ninds.nih.gov › health-information › sotos-sy...https://www.ninds.nih.gov › health-information › sotos-sy...
Sequencing and mapping efforts have already revealed that chromosome 22 is implicated in the workings of the immune system, congenital heart disease, schizophrenia, mental retardation, birth defects, and several cancers including leukemia.NIH News Release: Human Chromosome 22: First to be Decodedhttps://web.ornl.gov › Human_Genome › project › chr22https://web.ornl.gov › Human_Genome › project › chr22
Chromosome 8 is one of the 23 pairs of chromosomes in humans. People normally have two copies of this chromosome. Chromosome 8 spans about 145 million base pairs (the building material of DNA) and represents between 4.5 and 5.0% of the total DNA in cells....Chromosome 8GenBankCM000670 (FASTA)19 more rowsChromosome 8 - Wikipediahttps://en.wikipedia.org › wiki › Chromosome_8https://en.wikipedia.org › wiki › Chromosome_8
Other deletions of part of a chromosome 1 Q93.5 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. 2 The 2021 edition of ICD-10-CM Q93.5 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of Q93.5 - other international versions of ICD-10 Q93.5 may differ.
A genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures. The majority of cases result from deletions on the long arm of chromosome 15.
Q93.2 is a billable ICD code used to specify a diagnosis of chromosome replaced with ring, dicentric or isochromosome. A 'billable code' is detailed enough to be used to specify a medical diagnosis.
The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions.
22q13 deletion syndrome (spoken as twenty-two q one three) is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion should be diagnosed as 22q13 deletion syndrome. 22q13 deletion syndrome is often placed in the more general category of Phelan-McDermid Syndrome (abbreviated PMS), which includes some mutations and microdeletions. The PMS name is less precise, since there is disagreement among researchers as to which variants belong in the PMS category. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions. This latter definition of PMS is incompatible with the defintion of 22q13 deletion syndrome by those who first described 22q13 deletion syndrome.
Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis. The Center for Medicare & Medicaid Services (CMS) requires medical coders to indicate whether or not a condition was present at the time of admission, in order to properly assign MS-DRG codes.
The Phelan-McDermid Syndrome Foundation’s (PMSF) goal is to find effective clinical therapies and, eventually, a cure. In 2010, the PMSF launched a strategic plan for science to accelerate PMS research.
As children grow, additional symptoms develop. People with PMS typically have moderate to severe developmental and intellectual impairment, most do not acquire functional language, and about 75% have been diagnosed with an autism spectrum disorder.
Parents should undergo metaphase FISH and/or karyotype testing to determine if the child’s deletion is de novo (spontaneous) or if it resulted from a parental chromosomal rearrangement, such as a balanced translocation or inversion, or if one of the parents themselves has the same deletion.
Phelan-McDermid syndrome (PMS) is a rare genetic condition caused by a deletion or other structural change of the terminal end of chromosome 22 in the 22 q13 region or a disease-causing mutation of the SHANK3 gene. Although the range and severity of symptoms may vary, PMS is generally thought to be characterized by neonatal hypotonia (low muscle tone in the newborn), normal growth, absent to severely delayed speech, moderate to profound developmental delay, and minor dysmorphic features.
The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions.
22q13 deletion syndrome (spoken as twenty-two q one three) is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations (phenotype) typical of a terminal deletion should be diagnosed as 22q13 deletion syndrome. 22q13 deletion syndrome is often placed in the more general category of Phelan-McDermid Syndrome (abbreviated PMS), which includes some mutations and microdeletions. The PMS name is less precise, since there is disagreement among researchers as to which variants belong in the PMS category. The Developmental Synaptopathies Consortium defines PMS as being caused by SHANK3 mutations, a definition that excludes terminal deletions. This latter definition of PMS is incompatible with the defintion of 22q13 deletion syndrome by those who first described 22q13 deletion syndrome.
Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis. The Center for Medicare & Medicaid Services (CMS) requires medical coders to indicate whether or not a condition was present at the time of admission, in order to properly assign MS-DRG codes.
Affected individuals present with a broad array of medical and behavioral manifestations (tables 1 and 2). Patients are consistently characterized by global developmental delay, intellectual disability, speech abnormalities, ASD -like behaviors, hypotonia and mild dysmorphic features.
Various deletions affect the terminal region of the long arm of chromosome 22 (the paternal chromosome in 75% of cases ), from 22q13.3 to 22qter. Although the deletion is most typically a result of a de novo mutation, there is an inherited form resulting from familial chromosomal translocations involving the 22 chromosome.
The true prevalence of PMS has not been determined. More than 1,200 people have been identified worldwide according to the Phelan–McDermid Syndrome Foundation. However, it is believed to be underdiagnosed due to inadequate genetic testing and lack of specific clinical features. It is known to occur with equal frequency in males and females.
The first case of PMS was described in 1985 by Watt et al., who described a 14-year-old boy with severe intellectual disability, mild dysmorphic features and absent speech, which was associated with terminal loss of the distal arm of chromosome 22. In 1988, Phelan et al.